Table 1.
Baseline characteristics. The median duration of acalabrutinib use was 41.2 months
| Variable | Total (n = 280) |
No baseline HTN (n = 115) | Baseline HTN (n = 165) |
|---|---|---|---|
| Age at acalabrutinib initiation, mean (SD) | 63.7 (10.1) | 61.5 (10.9) | 65.2 (9.3) |
| Sex, n (%) | |||
| Male | 199 (71.1) | 79 (68.7) | 120 (72.7) |
| Female | 81 (28.9) | 36 (31.3) | 45 (27.3) |
| Race, n (%) | |||
| White | 270 (96.8) | 111 (96.5) | 159 (97.0) |
| Black | 5 (1.8) | 3 (2.6) | 2 (1.2) |
| Other* | 5 (1.8) | 1 (0.9) | 4 (2.4) |
| BMI, mean (SD) | 28.1 (5.5) | 26.2 (4.5) | 29.5 (5.8) |
| BMI, n (%) | |||
| < 25 | 78 (27.9) | 43 (37.4) | 35 (21.2) |
| 25–29.9 | 116 (41.4) | 53 (46.1) | 63 (38.2) |
| ≥ 30 | 86 (30.7) | 19 (16.5) | 67 (40.6) |
| Other baseline traditional HTN risk factors | |||
| DM | 24 (8.6) | 9 (7.8) | 15 (9.1) |
| MI | 12 (4.3) | 4 (3.5) | 8 (4.8) |
| CKD | 7 (2.5) | 3 (2.6) | 4 (2.4) |
| CHF | 12 (4.3) | 4 (3.5) | 8 (4.8) |
| AF/Aflutter | 40 (14.3) | 16 (13.9) | 24 (14.5) |
| CVA/TIA | 7 (2.5) | 3 (2.6) | 4 (2.4) |
| Smoking status | |||
| Never | 166 (59.3) | 79 (68.7) | 87 (52.7) |
| Previous | 93 (33.2) | 27 (23.5) | 66 (40.0) |
| Current | 21 (7.5) | 9 (7.8) | 12 (7.3) |
| Primary malignancy, n (%) | |||
| CLL | 249 (88.9) | 104 (90.4) | 145 (87.9) |
| MCL | 6 (2.1) | 2 (1.7) | 4 (2.4) |
| Other† | 25 (8.9) | 9 (7.8) | 16 (9.7) |
| RAI stage, n (%)** | |||
| 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 1 | 43 (15.4) | 20 (17.4) | 23 (13.9) |
| 2 | 46 (16.4) | 18 (15.7) | 28 (17.0) |
| 3 | 27 (9.6) | 15 (13.0) | 12 (7.3) |
| 4 | 90 (32.1) | 38 (33.0) | 52 (31.5) |
| Unknown | 74 (26.4) | 24 (20.9) | 50 (30.3) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 107 (38.2) | 43 (37.4) | 64 (38.8) |
| 1 | 164 (58.6) | 68 (59.1) | 96 (58.2) |
| 2 | 8 (2.9) | 3 (2.6) | 5 (3.0) |
| 3 | 1 (0.4) | 1 (0.9) | 0 (0.0) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Treatment history, n (%) | |||
| Number of prior anticancer therapies, median (IQR) | 2 (2) | 2 (3) | 2 (2) |
| Concomitant chemotherapy | 99 (35.4) | 42 (36.5) | 57 (34.5) |
| Prior chemotherapy | 137 (48.9) | 53 (46.1) | 84 (50.9) |
| Prior monoclonal antibody | 171 (61.1) | 72 (62.6) | 99 (60.0) |
| Prior ibrutinib therapy | 72 (25.7) | 26 (22.6) | 46 (27.9) |
| Prior targeted therapy (not Ibrutinib) | 26 (9.3) | 12 (10.4) | 14 (8.5) |
| Prior immunomodulatory | 31 (11.1) | 16 (13.9) | 15 (9.1) |
| CY3PA4 inhibitor | 27 (9.6) | 8 (7.0) | 19 (11.5) |
| Cyclosporine during ibrutinib use | 4 (1.4) | 1 (0.9) | 3 (1.8) |
| No prior anticancer therapies, n (%) | 77 (27.5) | 33 (28.7) | 44 (26.7) |
| Baseline SBP, mmHg | |||
| < 100 | 6 (2.1) | 6 (5.2) | 0 (0.0) |
| 100–119 | 75 (26.8) | 73 (63.5) | 2 (1.2) |
| 120–129 | 68 (24.3) | 36 (31.3) | 32 (19.4) |
| 130–139 | 50 (17.9) | 0 (0.0) | 50 (30.3) |
| 140–179 | 78 (27.9) | 0 (0.0) | 78 (47.3) |
| 180 + | 3 (1.1) | 0 (0.0) | 3 (1.8) |
| Baseline DBP, mmHg | |||
| < 70 | 124 (44.3) | 78 (67.8) | 46 (27.9) |
| 70–79 | 101 (36.1) | 33 (28.7) | 68 (41.2) |
| 80–89 | 44 (15.7) | 4 (3.5) | 40 (24.2) |
| 90–119 | 11 (3.9) | 0 (0.0) | 11 (6.7) |
| Baseline anti-HTN medications | |||
| Beta-blocker | 67 (23.9) | 25 (21.7) | 42 (25.5) |
| ACE inhibitor/ARB | 80 (28.6) | 21 (18.3) | 59 (35.8) |
| Calcium channel blocker | 29 (10.4) | 5 (4.3) | 24 (14.5) |
| Diuretic‡ | 46 (16.4) | 11 (9.6) | 35 (21.2) |
| Other§ | 10 (3.5) | 2 (1.7) | 8 (4.8) |
ACE angiotensin-converting enzyme inhibitor, AF atrial fibrillation, Aflutter atrial flutter, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, CKD chronic kidney disease, CLL chronic lymphocytic lymphoma, CVA cerebrovascular accident, CY3PA4 cytochrome P450, family 3, subfamily A, DBP diastolic blood pressure, DM diabetes mellitus, ECOG Eastern Cooperative Oncology Group, HTN hypertension, MCL mantle cell lymphoma, MI myocardial infarction, TIA transient ischemic attack, WM Waldenström’s macroglobulinemia
*Hispanic, Asian, multiracial, and unknown race. **CLL alone. †Diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, graft-versus-host disease, and marginal zone lymphoma. ‡Includes loop, thiazide, and potassium-sparing diuretics. §Clonidine, hydralazine, nitrates, and alpha-1 antagonists